BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 9357448)

  • 1. Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller Fisher syndrome.
    Jacobs BC; Endtz HP; van der Meché FG; Hazenberg MP; de Klerk MA; van Doorn PA
    J Neuroimmunol; 1997 Oct; 79(1):62-8. PubMed ID: 9357448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivity of serum IgG anti-GM1 ganglioside antibodies with the lipopolysaccharide fractions of Campylobacter jejuni isolates from patients with Guillain-Barre syndrome (GBS).
    Gregson NA; Rees JH; Hughes RA
    J Neuroimmunol; 1997 Mar; 73(1-2):28-36. PubMed ID: 9058756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome.
    Yuki N
    J Infect Dis; 1997 Dec; 176 Suppl 2():S150-3. PubMed ID: 9396700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher's syndromes.
    Koga M; Yuki N; Takahashi M; Saito K; Hirata K
    J Neuroimmunol; 1998 Jan; 81(1-2):138-43. PubMed ID: 9521615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome.
    Yuki N; Ichihashi Y; Taki T
    J Neuroimmunol; 1995 Jul; 60(1-2):161-4. PubMed ID: 7543907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis.
    Yuki N
    Jpn J Infect Dis; 1999 Jun; 52(3):99-105. PubMed ID: 10507987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.
    Ang CW; De Klerk MA; Endtz HP; Jacobs BC; Laman JD; van der Meché FG; van Doorn PA
    Infect Immun; 2001 Apr; 69(4):2462-9. PubMed ID: 11254608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.
    Schwerer B; Neisser A; Bernheimer H
    Infect Immun; 1999 May; 67(5):2414-20. PubMed ID: 10225903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.
    Jacobs BC; Hazenberg MP; van Doorn PA; Endtz HP; van der Meché FG
    J Infect Dis; 1997 Mar; 175(3):729-33. PubMed ID: 9041356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guillain-Barré syndrome and Fisher's syndrome following Campylobacter jejuni infection.
    Yuki N; Miyatake T
    Ann N Y Acad Sci; 1998 Jun; 845():330-40. PubMed ID: 9668366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Campylobacter jejuni enteritis and Guillain-Barré syndrome].
    Yuki N
    Rinsho Byori; 1999 Aug; 47(8):713-8. PubMed ID: 10511801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current cases in which epitope mimicry is considered a component cause of autoimmune disease: Guillain-Barré syndrome.
    Yuki N
    Cell Mol Life Sci; 2000 Apr; 57(4):527-33. PubMed ID: 11130452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients.
    Ang CW; Laman JD; Willison HJ; Wagner ER; Endtz HP; De Klerk MA; Tio-Gillen AP; Van den Braak N; Jacobs BC; Van Doorn PA
    Infect Immun; 2002 Mar; 70(3):1202-8. PubMed ID: 11854201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside.
    Prendergast MM; Lastovica AJ; Moran AP
    Infect Immun; 1998 Aug; 66(8):3649-55. PubMed ID: 9673245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barré syndrome after Campylobacter jejuni enteritis.
    Koga M; Yuki N; Hirata K
    J Neuroimmunol; 1999 May; 96(2):245-50. PubMed ID: 10337924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies.
    Prendergast MM; Moran AP
    J Endotoxin Res; 2000; 6(5):341-59. PubMed ID: 11521055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Campylobacter lipopolysaccharide bearing a GD3 epitope essential for the pathogenesis of Guillain-Barré syndrome?
    Yuki N; Koga M; Hirata K
    Acta Neurol Scand; 2000 Aug; 102(2):132-4. PubMed ID: 10949532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome.
    Yuki N; Handa S; Tai T; Takahashi M; Saito K; Tsujino Y; Taki T
    J Neurol Sci; 1995 May; 130(1):112-6. PubMed ID: 7544402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes.
    Kanzaki M; Kaida K; Ueda M; Morita D; Hirakawa M; Motoyoshi K; Kamakura K; Kusunoki S
    J Neurol Neurosurg Psychiatry; 2008 Oct; 79(10):1148-52. PubMed ID: 18339728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Campylobacter jejuni lipopolysaccharides from Guillain-Barré syndrome patients induce IgG anti-GM1 antibodies in rabbits.
    Ang CW; Endtz HP; Jacobs BC; Laman JD; de Klerk MA; van der Meché FG; van Doorn PA
    J Neuroimmunol; 2000 May; 104(2):133-8. PubMed ID: 10713352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.